According to Zacks, “Novadaq Technologies Inc. develops, manufactures and markets real-time fluorescence imaging products for use in the operating room and other clinical settings. The company’s key markets include plastic reconstructive, gastrointestinal, cardiac and general surgery. It provides SPY imaging systems which enables surgeons to the visualize blood flow in vessels, co-joined vessels and micro-vessels. Novadaq Technologies Inc. is headquartered in Mississauga, Canada. “
NVDQ has been the subject of several other research reports. Wedbush restated a positive rating and set a $17.00 price target on shares of Novadaq Technologies in a report on Tuesday, September 20th. Canaccord Genuity reaffirmed a buy rating and issued a $15.00 price objective on shares of Novadaq Technologies in a research note on Monday, August 29th. Northland Securities reaffirmed an underperform rating and issued a $7.00 price objective on shares of Novadaq Technologies in a research note on Thursday, July 7th. Finally, Feltl & Co. raised Novadaq Technologies from a buy rating to a strong-buy rating in a research note on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $13.42.
Novadaq Technologies (NASDAQ:NVDQ) traded down 0.39% during trading on Wednesday, hitting $10.31. The stock had a trading volume of 4,720 shares. The stock’s market cap is $592.15 million. Novadaq Technologies has a 12 month low of $8.26 and a 12 month high of $14.36. The stock has a 50 day moving average price of $11.64 and a 200-day moving average price of $10.78.
Novadaq Technologies (NASDAQ:NVDQ) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.15. The firm had revenue of $20.12 million for the quarter, compared to analysts’ expectations of $19.97 million. Novadaq Technologies had a negative net margin of 49.45% and a negative return on equity of 25.28%. The business’s quarterly revenue was up 33.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) EPS. On average, equities analysts predict that Novadaq Technologies will post ($0.73) EPS for the current year.
Several large investors have recently modified their holdings of the company. Geduld E E raised its stake in shares of Novadaq Technologies by 20.0% in the second quarter. Geduld E E now owns 15,000 shares of the company’s stock worth $148,000 after buying an additional 2,500 shares in the last quarter. Wrapmanager Inc. increased its position in Novadaq Technologies by 24.0% in the second quarter. Wrapmanager Inc. now owns 20,496 shares of the company’s stock valued at $202,000 after buying an additional 3,968 shares during the last quarter. US Bancorp DE increased its position in Novadaq Technologies by 5.9% in the second quarter. US Bancorp DE now owns 20,725 shares of the company’s stock valued at $203,000 after buying an additional 1,161 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Novadaq Technologies by 813.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 24,854 shares of the company’s stock valued at $245,000 after buying an additional 22,132 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Novadaq Technologies by 8.0% in the first quarter. Geode Capital Management LLC now owns 22,372 shares of the company’s stock valued at $248,000 after buying an additional 1,665 shares during the last quarter. 88.63% of the stock is owned by hedge funds and other institutional investors.
About Novadaq Technologies
Novadaq Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.